Shark-Derived VNAR Immunotoxins Take Aim at TROP-2 Cancers
Researchers have developed a recombinant immunotoxin targeting the human trophoblast cell surface antigen 2 (TROP-2) using a shark-derived variable domain of immunoglobulin new antigen receptor. TROP-2 is a transmembrane glycoprotein that regulates multiple signaling pathways and mediates tumor migration in epithelial tumors.
Overcoming Traditional Antibody Drug Limitations With VNAR Antibodies
Traditional antibody–drug conjugates rely on IgG antibodies that possess high molecular weights, which often leads to poor tumor penetration and off-target toxicity from released cytotoxic molecules. To counteract these limitations, investigators created a shark VNAR phage display library that yielded the high-affinity binder designated as shark VNAR-5G8. VNAR antibodies are approximately one-tenth the size of conventional IgG antibodies, giving them distinct advantages in tissue penetration and thermal stability while avoiding the hydrophobic interfaces common in single-chain variable fragments derived from IgG.
Researchers Fuse 5G8 Antibody with PE38 Toxin
Epitope analysis revealed that the 5G8 binder recognizes a hidden epitope consisting of the cysteine-rich domain and the TY-1 region on TROP-2. Researchers subsequently fused the VNAR-5G8 antibody with a truncated form of Pseudomonas exotoxin known as PE38 to construct the recombinant immunotoxin 5G8-PE38.
Comparative Efficacy Against Existing TROP-2 Treatments
Sacituzumab Govitecan stands as the first TROP-2 targeted antibody-drug conjugate approved for advanced triple-negative breast cancer. Several clinical trials continue to evaluate similar agents like Datopotamab deruxtecan and SKB264 in patients with TROP-2 positive tumors. While those conventional therapies depend on whole IgG frameworks, the novel shark-derived immunotoxin approach utilizes a single-domain architecture to streamline intracellular delivery and minimize the off-target systemic toxicity historically linked to standard cytotoxic payload release.
Frequently Asked Questions About Shark VNAR Immunotoxins
What is the specific role of the PE38 component in 5G8-PE38?
PE38 is a truncated, less immunogenic variant of Pseudomonas exotoxin A. It functions as the toxic ligand that induces cell death once the immunotoxin successfully internalizes into the target cancer cell.
Which specific domains on TROP-2 does the 5G8 binder recognize?
Epitope analysis shows that the shark-derived VNAR-5G8 targets a concealed epitope comprising the cysteine-rich domain and the TY-1 region of the TROP-2 protein.
Keep reading